English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Meeting Abstract

GLINT: GlucoCEST in neoplastic tumours at 3T - first-in-man studies of GlucoCEST in glioma patients

MPS-Authors
/persons/resource/persons214560

Zaiss,  M
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;
Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons216025

Herz,  K
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;
Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons215996

Deshmane,  A
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;
Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons84187

Scheffler,  K
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;
Max Planck Institute for Biological Cybernetics, Max Planck Society;

Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Lindig, T., Zaiss, M., Herz, K., Deshmane, A., Bender, B., Golay, X., et al. (2019). GLINT: GlucoCEST in neoplastic tumours at 3T - first-in-man studies of GlucoCEST in glioma patients. Insights into Imaging, 10(Supplement 1): B-0095, S206.


Cite as: http://hdl.handle.net/21.11116/0000-0003-23B3-B
Abstract
Purpose: Dynamic glucose enhanced (DGE) CEST imaging has almost only been shown at ultra-high field (UHF) due to low effect size. First results in brain tumour patients of a DGE CEST method with fast 3D imaging developed for clinical field strength are shown herein. Methods and Materials: CEST saturated images at different frequency offsets were acquired at 160 time points before, during and after a glucose injection (0.3 mg/kg) with 6.3s temporal resolution (Total: 16:45 min) to detect accumulation in the brain. Two glioblastoma (IDH wild-type, unmethylated MGMT promoter) patients (1: male, 70y, 2: female, 75y) and 3 healthy controls were scanned at a clinical 3T System. DGE contrast images were analysed by subtracting each image from a pre-injection baseline image: ΔDGE(t)=DGEbaseline - DGE(t). Results: In the high-grade glioma (1), glucose uptake in the Gadolinium enhancing region could be detected approximately 4 minutes after injection with a maximum increase of ΔDGE=0.51±0.078, whereas a contralateral white matter ROI was barely affected (ΔDGE=0.07±0.085) at the same time point. The second glioma (2), with the same histology and grading, showed very little gadolinium enhancement as well as no significant detectable DGE effect. Healthy controls did not show any significant DGE contrast. Conclusion: We demonstrated that stable dynamic glucose enhanced imaging can be accomplished at clinical field strength using optimized saturation and readout parameters. First results are promising, and indicate that glucoCEST corresponds more to the disruptions of the blood-brain-barrier with Gadolinium uptake than to the molecular tumour profile or tumour grading.